ARTICLE | Clinical News
rectal TOP1288: Phase IIa started
October 17, 2016 7:00 AM UTC
TopiVert began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 200 mg TOP1288 rectal solution once daily for 4 weeks in about 60 patients with moderate to severe disease activ...